1 |
RAFIKOVA G, GILYAZOVA I, ENIKEEVA K, et al. Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers[J]. Int J Mol Sci, 2023, 24(16):12797. doi:10.3390/ijms241612797
doi: 10.3390/ijms241612797
|
2 |
BERGENGREN O, PEKALA K R, MATSOUKAS K, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review[J]. Eur Urol, 2023, 84(2):191-206. doi:10.1016/j.eururo.2023.04.021
doi: 10.1016/j.eururo.2023.04.021
|
3 |
SEKHOACHA M, RIET K, MOTLOUNG P, et al. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches[J]. Molecules, 2022, 27(17):5730-5742. doi:10.3390/molecules27175730
doi: 10.3390/molecules27175730
|
4 |
WU M, HUANG Y, CHEN T, et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis[J]. J Cell Mol Med, 2019, 23(1):29-38. doi:10.1111/jcmm.13658
doi: 10.1111/jcmm.13658
|
5 |
TAN Y T, LIN J F, LI T, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer[J]. Cancer Commun (Lond), 2021, 41(2):109-120. doi:10.1002/cac2.12108
doi: 10.1002/cac2.12108
|
6 |
LI L, LI Y, HUANG Y, et al. Long non-coding RNA MIF-AS1 promotes gastric cancer cell proliferation and reduces apoptosis to upregulate NDUFA4[J]. Cancer Sci, 2018, 109(12):3714-3725. doi:10.1111/cas.13801
doi: 10.1111/cas.13801
|
7 |
WANG B, ZHANG Y, YE M, et al. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner[J]. Curr Drug Metab, 2019, 20(10):804-814. doi:10.2174/1389200220666190819151946
doi: 10.2174/1389200220666190819151946
|
8 |
FERRI C, DI BIASE A, BOCCHETTI M, et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer[J]. J Exp Clin Cancer Res, 2022, 41(1):20-32. doi:10.1186/s13046-021-02233-w
doi: 10.1186/s13046-021-02233-w
|
9 |
KAY E J, PATERSON K, RIERA-DOMINGO C, et al. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix[J]. Nat Metab, 2022, 4(6):693-710. doi:10.1038/s42255-022-00582-0
doi: 10.1038/s42255-022-00582-0
|
10 |
张丽红, 胡良峰, 杨烨, 等. PYCR1在肝癌中的表达特点及其临床价值[J]. 医学研究杂志, 2023, 52(2):76-80.
|
11 |
SCHATTEN H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies[J]. Adv Exp Med Biol, 2018, 1095(1):1-14.
|
12 |
VIETRI M T, D'ELIA G, CALIENDO G, et al. Hereditary prostate cancer: Genes related, target therapy and prevention[J]. Int J Mol Sci, 2021, 22(7):3753-3762. doi:10.3390/ijms22073753
doi: 10.3390/ijms22073753
|
13 |
MCCABE E M, RASMUSSEN T P. lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions[J]. Semin Cancer Biol, 2021, 75(1):38-48. doi:10.1016/j.semcancer.2020.12.012
doi: 10.1016/j.semcancer.2020.12.012
|
14 |
HAGHIGHI R, CASTILLO-ACOBO R Y, AMIN A H, et al. A thorough understanding of the role of lncRNA in prostate cancer pathogenesis; Current knowledge and future research directions[J]. Pathol Res Pract, 2023, 248:154666. doi:10.1016/j.prp.2023.154666
doi: 10.1016/j.prp.2023.154666
|
15 |
YANG G, LI T, LIU J, et al. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis[J]. Genomics, 2023, 115(2):110599. doi:10.1016/j.ygeno.2023.110599
doi: 10.1016/j.ygeno.2023.110599
|
16 |
NI P, WANG G, WANG Y, et al. Correlation of MIF-AS1 polymorphisms with the risk and prognosis of gastric cancer[J]. Pathol Res Pract, 2022, 233(1):153-163. doi:10.1016/j.prp.2022.153850
doi: 10.1016/j.prp.2022.153850
|
17 |
FAN Y, WANG L, HAN X C, et al. LncRNA MIF-AS1 aggravates the progression of ovarian cancer by sponging miRNA-31-5p[J]. Eur Rev Med Pharmacol Sci, 2020, 24(5):2248-2255.
|
18 |
GUO Y, ZHOU X, GAO F, et al. MiR-423-5p is a novel endogenous control for the quantification of circulating miRNAs in human esophageal squamous cell carcinoma[J]. Heliyon, 2023, 9(4):e14515. doi:10.1016/j.heliyon.2023.e14515
doi: 10.1016/j.heliyon.2023.e14515
|
19 |
WANG Q, WANG L X, ZHANG C Y, et al. LncRNA CRNDE promotes cell proliferation, migration and invasion of ovarian cancer via miR-423-5p/FSCN1 axis[J]. Mol Cell Biochem, 2022, 477(5):1477-1488. doi:10.1007/s11010-022-04382-8
doi: 10.1007/s11010-022-04382-8
|
20 |
JIANG F, HU X, CAO H, et al. Hsa_circ_0000081 promotes the function of gastric cancer through sponging hsa-miR-423-5p to influence 3-phosphoinositide-dependent kinase 1 expression[J]. Bioengineered, 2022, 13(4):8277-8290. doi:10.1080/21655979.2022.2053796
doi: 10.1080/21655979.2022.2053796
|
21 |
XUE S T, ZHENG B, CAO S Q, et al. Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis[J]. Mol Cancer, 2022, 21(1):69-78. doi:10.1186/s12943-022-01539-3
doi: 10.1186/s12943-022-01539-3
|
22 |
SHANG Y, WANG L, ZHU Z, et al. Downregulation of miR-423-5p Contributes to the Radioresistance in Colorectal Cancer Cells[J]. Front Oncol, 2021, 10(1):582-590. doi:10.3389/fonc.2020.582239
doi: 10.3389/fonc.2020.582239
|
23 |
CUI B, HE B, HUANG Y, et al. Pyrroline-5-carboxylate reductase 1 reprograms proline metabolism to drive breast cancer stemness under psychological stress[J]. Cell Death Dis, 2023, 14(10):682. doi:10.1038/s41419-023-06200-5
doi: 10.1038/s41419-023-06200-5
|
24 |
程秋华, 周帅, 向杨, 等. PYCR1基因在肝细胞癌中的表达及与预后的关系[J]. 实用医学杂志, 2021, 37(2):233-237.
|
25 |
DU S, SUI Y, REN W, et al. PYCR1 promotes bladder cancer by affecting the Akt/Wnt/β-catenin signaling[J]. J Bioenerg Biomembr, 2021, 53(2):247-258. doi:10.1007/s10863-021-09887-3
doi: 10.1007/s10863-021-09887-3
|
26 |
XU H, HE Y, LIN L, et al. MiR-1207-5p targets PYCR1 to inhibit the progression of prostate cancer[J]. Biochem Biophys Res Commun, 2021, 575:56-64. doi:10.1016/j.bbrc.2021.08.037
doi: 10.1016/j.bbrc.2021.08.037
|